SEC Info - AC Immune SA - ‘6-K’ for 4/2/20

SEC Info℠

Home

Help

Please Sign In

AC Immune SA – ‘6-K’ for 4/2/20

On: Thursday, 4/2/20, at 7:11am ET · For: 4/2/20 · Accession #: 950103-20-6760 · File #: 1-37891

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/02/20  AC Immune SA                      6-K         4/02/20    2:112K                                   Davis Polk & … LLP 01/FA

Current Report by a Foreign Issuer — Form 6-K — Rule 13a-16 / 15d-16
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current Report by a Foreign Issuer                  HTML     10K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     19K

‘6-K’ — Current Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2020

Commission File Number: 001-37891

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

AC IMMUNE SA

This report on Form 6-K (including Exhibits 99.1 hereto) shall be deemed to be incorporated by reference into the registration on Form F-3 (Registration Number: 333-224694), the registration statement on Form F-3 (Registration Number: 333-227016) and the registration statement on Form S-8 (Registration Number: 333-216539) of AC Immune and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA


By:	/s/ *Andrea Pfeifer*
	Name:	Andrea Pfeifer
	Title:	Chief Executive Officer


By:	/s/ *Joerg Hornstein*
	Name:	Joerg Hornstein
	Title:	Chief Financial Officer

Date: April 2, 2020

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated April 2, 2020

Dates Referenced Herein and Documents Incorporated by Reference

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	4/2/20	None on these Dates
		List all Filings

↑Top

Filing Submission 0000950103-20-006760 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)